
|
|
|
|
|
|
|
*A 20-week, multicenter, randomized clinical trial compared adult and pediatric subjects with type 1 and type 2 diabetes and A1C ≥8.0%, followed by a 46-week nonrandomized observational study. Patients were randomized to use the OneTouch® UltraSmart® Meter (n=113) or conventional meters and paper logbooks (n=93). Both groups received monthly counseling from health care providers during the 20-week clinical trial and returned to usual care during the observational follow-up. In the 20-week study, both groups saw a reduction in A1C; however, the reduction in the OneTouch® UltraSmart® group was significantly greater (-0.6 vs -0.4) (p = 0.03). In the observational study, subjects who chose to continue with the OneTouch® UltraSmart® Meter (n=42) showed a sustained reduction in A1C over subjects who chose to continue with conventional meters and paper logbooks (n=28) (8.47% vs 9.25%, p=0.006). The study did not evaluate whether this change in A1C will result in improved health outcomes.
†Average savings over strips in the non-preferred coverage category.
‡Some health plans may have more than one brand covered at the lowest co-pay.
1. LifeScan data on file. Self-monitoring of blood glucose study #1: The ability of people with diabetes to use OneTouch® UltraSmart® to improve glycemic control through behavioral and therapeutic changes (RPT 1039775, Nov. 2004) and Addendum #1 (Nov. 2005).